Augmentation of Humoral Immunity Using Toll-Like Receptor (TLR) 9 Adjuvanted HBV Surface Antigen to Enhance Anti-HBSAg Response
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Safety and reactogenicity of the Hepatitis B Virus Surface Antigen, Recombinant (HEPLISAV-B; Dynavax Technologies Corporation) Vaccine in patients with chronic hepatitis B
研究概览
简要总结
The goal of this clinical trial is to learn if HEPLISAV-B, a vaccine that is approved to prevent hepatitis B infection in people that are not already infected, is safe in people already chronically infected with hepatitis B. The main quiestions it aims to answer are:
- Is HEPLISAV-B safe in people with chronic hepatitis B?
- What side effects, if any, could HEPLISAV-B cause in people with chronic hepatitis B?
- How does HEPLISAV-B affect the cells that fight chronic hepatitis B?
Participants will:
- Receive HEPLISAV-B as an injection in the muscle, one injection every 4 weeks, for a total of 2 injections.
- Visit the clinic a total of 5 times, and have 3 phone follow ups over 14 months.
- Be asked if they are having any side effects from HEPLISAV-B.
- Have blood samples collected.
详细描述
Ten people with chronic hepatitis B and virally suppressed on nucleos(t)ide analogue (NUC) therapy will receive a total of two 0.5ml intramuscular injections of HEPLISAV-B, a CpG-adjuvanted vaccine, the first injection on day 0, and the second injection on week 4.
Participants will visit the clinic on day 0, and weeks 2, 4, 8, and 28. They will also have phone follow ups on day 7, and weeks 5 and 56. At each follow up, participants will be asked about any side effects. At each clinic visit blood samples will be collected. For 7 days after each HEPLISAV-B injection, participants will complete a diary to document any reactions to the injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •In order to participate in this study, an individual must meet all the following criteria:
- •>18 years old
- •Diagnosed with CHB infection, without HIV, hepatitis C nor hepatitis D co-infections
- •Currently receiving NUC with HBV VL <100 IU/ml for ≥ 12 months
- •Willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, and other study procedures.
- •Determined by medical history, targeted physical examination, and clinical judgement of the investigator to be in good health.
- •CHB infection is defined as any individual with documentation of a positive HBsAg and/or detectable HBV DNA test for at least 6 months.
排除标准
- •A participant will be ineligible to participate on this study if any of the following criteria are met:
- •Pregnancy or breast feeding.
- •Received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids ≥ 20 mg/day of prednisone equivalent). Received anti-CD20 immunosuppressant within 12 months of screening. Topical tacrolimus is allowed if not used within 14 days prior to Day
- •Received or plans to receive live virus vaccines within 4 weeks, and inactivated vaccine within 2 weeks prior to randomization; or plans to receive a non-study vaccine within 28 days after any dose of study vaccine (with exception for seasonal influenza vaccine within 14 days of study vaccine).
- •Administration of any blood products within 3 months prior to randomization.
- •Participation in a study with an investigational study product or device within 30 days of randomization.
- •Has allergies to any hepatitis B and/or yeast-based vaccines.
- •Subjects meeting any of the following laboratory parameters at screening:
- •ALT greater than 3 times the upper limit of normal
- •Elevated total bilirubin WITH direct bilirubin greater than 2 times upper limit of normal
- •Is acutely ill or febrile 72 hours prior to or at vaccine dosing (fever defined as ≥ 38.0°C/100.4°F). Participants meeting this criterion may be rescheduled within the relevant window periods. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
- •Have any chronic or acute or unstable conditions that the investigator considers a contraindication to study participation.
研究组 & 干预措施
Intervention
HEPLISAV-B is available in pre-filled, single-dose 0.5 mL vials. Each dose contains 20 μg of HBsAg and 3,000 μg of 1018 adjuvant. HEPLISAV-B is administered as an intramuscular injection in the deltoid region.
Study subjects will receive a total of 2 injections, each administered at least 4 weeks apart - the same dosing schedule recommended for hepatitis B prevention.
Once enrolled, participants will have study visits on days 0 (first injection), and weeks 2, 4 (second injection), 8, and 28. They will also have phone follow ups on day 7 and week 5 (7 days after each injection) and week 56 (end of study).
干预措施: Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B] (Drug)
结局指标
主要结局
Safety and reactogenicity of the Hepatitis B Virus Surface Antigen, Recombinant (HEPLISAV-B; Dynavax Technologies Corporation) Vaccine in patients with chronic hepatitis B
时间窗: Baseline to 7 days following each vaccine dose
Number of local and systemic solicited adverse events
Occurence of unsolicited adverse events
时间窗: from dose 1 to 28 days following each vaccine dose
Number of unsolicited adverse events
Medically Attended Adverse Events
时间窗: From first vaccine to 12 months after last vaccine on study.
Number of Medically Attended Adverse Events (MAAEs)
次要结局
未报告次要终点
研究者
Lydia Tang
Assistant Professor
University of Maryland, Baltimore